{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T16:36:10Z","timestamp":1720802170982},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,10]]},"DOI":"10.18632\/oncotarget.13754","type":"journal-article","created":{"date-parts":[[2016,12,3]],"date-time":"2016-12-03T23:10:14Z","timestamp":1480806614000},"page":"3304-3314","source":"Crossref","is-referenced-by-count":4,"title":["Depression of oncogenecity by dephosphorylating and degrading BCR-ABL"],"prefix":"10.18632","volume":"8","author":[{"given":"Miao","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Molecular Medicine and Cancer Research, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Xi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Li","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by The Ministry of Education, Chongqing Medical University, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(86)90450-2","article-title":"Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene","volume":"47","author":"Canaani","year":"1986","journal-title":"Cell"},{"key":"2","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"Witte","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"McCubrey","year":"2004","journal-title":"Leukemia"},{"key":"4","first-page":"2563","article-title":"Cellular interactions of CRKL, and SH2-SH3 adaptor protein","volume":"54","author":"Groffen","year":"1994","journal-title":"Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Hong","year":"2015","journal-title":"Oncotarget"},{"key":"7","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib","volume":"105","author":"Deininger","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00726-012-1354-3","article-title":"TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization","volume":"44","author":"Feng","year":"2013","journal-title":"Amino Acids"},{"key":"9","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.18632\/oncotarget.1339","article-title":"Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus","volume":"4","author":"Feng","year":"2013","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Schlessinger","year":"1993","journal-title":"Cell"},{"key":"11","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/sj.onc.1201053","article-title":"Bcr phosphorylated on tyrosine 177 binds Grb2","volume":"14","author":"Arlinghaus","year":"1997","journal-title":"Oncogene"},{"key":"12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5966\/sctm.2012-0159","article-title":"Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors","volume":"3","author":"Ichim","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-4165(84)90009-6","article-title":"Protein tyrosine kinase and protein phosphotyrosine phosphatase in normal and psoriatic skin","volume":"798","author":"Chader","year":"1984","journal-title":"Biochim Biophys Acta"},{"key":"14","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.1067566","article-title":"Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum","volume":"295","author":"Bastiaens","year":"2002","journal-title":"Science"},{"key":"15","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/MCB.18.5.2965","article-title":"Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo","volume":"18","author":"Tonks","year":"1998","journal-title":"Mol Cell Biol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1432-1033.1994.tb19085.x","article-title":"Expression, purification and crystallization of human phosphotyrosine phosphatase 1B","volume":"223","author":"Huber","year":"1994","journal-title":"Eur J Biochem"},{"key":"17","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1021\/bi1014453","article-title":"Substrate specificity of protein tyrosine phosphatases 1B, RPTPalpha, SHP-1, and SHP-2","volume":"50","author":"Pei","year":"2011","journal-title":"Biochemistry"},{"key":"18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Chuah","year":"2007","journal-title":"Cancer Lett"},{"key":"19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428190801896210","article-title":"New therapeutic approaches and prognostic factors in chronic myeloid leukemia","volume":"49","author":"Rege-Cambrin","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"20","first-page":"484","article-title":"Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Chen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"22","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Bhalla","year":"2003","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"14982","DOI":"10.1073\/pnas.0507512102","article-title":"Method for targeting protein destruction by using a ubiquitin-independent, proteasome-mediated degradation pathway","volume":"102","author":"Reed","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.biocel.2012.02.008","article-title":"Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo","volume":"44","author":"Feng","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"25","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1038\/sj.leu.2401281","article-title":"Cell biology of CML cells","volume":"13","author":"Goldman","year":"1999","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(01)06902-1","article-title":"Imatinib for chronic myeloid leukaemia: a NICE mess","volume":"358","author":"O'Brien","year":"2001","journal-title":"Lancet"},{"key":"27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200208153470719","article-title":"Complete molecular remission in chronic myelogenous leukemia after imatinib therapy","volume":"347","author":"Simonsson","year":"2002","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Druker","year":"2005","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Sawyers","year":"2002","journal-title":"Cancer Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/10428190903518295","article-title":"Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice","volume":"51","author":"Attar","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.18632\/oncotarget.692","article-title":"All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib","volume":"3","author":"Lenain","year":"2012","journal-title":"Oncotarget"},{"key":"32","article-title":"Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities","author":"LeBoeuf","year":"2015","journal-title":"Br J Dermatol"},{"key":"33","first-page":"808","article-title":"Marketing and commercial distribution of ponatinib suspended following FDA request","volume":"11","author":"Small","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-011-0079-9","article-title":"New drugs for chronic myelogenous leukemia","volume":"6","author":"Quintas-Cardama","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"35","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.leukres.2014.09.016","article-title":"How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review","volume":"38","author":"Alimena","year":"2014","journal-title":"Leuk Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Salvatore","year":"2002","journal-title":"Oncogene"},{"key":"37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Bhatia","year":"2011","journal-title":"Leukemia"},{"key":"38","doi-asserted-by":"crossref","first-page":"e25139","DOI":"10.1371\/journal.pone.0025139","article-title":"Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis","volume":"6","author":"van der Kuip","year":"2011","journal-title":"PLoS ONE"},{"key":"39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12032-009-9267-z","article-title":"The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia","volume":"27","author":"Liu","year":"2010","journal-title":"Med Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Jiang","year":"2014","journal-title":"Oncotarget"},{"key":"41","first-page":"337","article-title":"[Establishment of an imatinib resistant cell line K562\/G01 and its characterization]","volume":"25","author":"Yang","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"He","year":"2007","journal-title":"Nat Protoc"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T13:56:16Z","timestamp":1589118976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1,10]]}},"alternative-id":["13754","27926512"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13754","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}